Form 8-K - Current report:
SEC Accession No. 0001564590-20-022882
Filing Date
2020-05-07
Accepted
2020-05-07 16:17:44
Documents
13
Period of Report
2020-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dvax-8k_20200507.htm   iXBRL 8-K 32945
2 EX-99.1 dvax-ex991_24.htm EX-99.1 128235
  Complete submission text file 0001564590-20-022882.txt   304217

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20200507.xsd EX-101.SCH 5772
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20200507_lab.xml EX-101.LAB 19478
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20200507_pre.xml EX-101.PRE 11627
6 EXTRACTED XBRL INSTANCE DOCUMENT dvax-8k_20200507_htm.xml XML 3558
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 20856679
SIC: 2834 Pharmaceutical Preparations